中期因子与宫颈癌的相关性研究

目的探讨中期因子（midkine，MK）在各种宫颈病变组织中的表达及其与宫颈癌临床病理学特征之间的关系。方法选取2004年1月至2007年3月四川大学华西第二医院病理科存档的141例石蜡标本为研究对象。采用免疫组化SP法，检测96例宫颈癌、15例宫颈上皮内瘤样变（cervical intraepithelial neoplasia，CIN）Ⅰ级（CINⅠ组）、15例宫颈上皮内瘤样变Ⅱ～Ⅲ级（CINⅡ～Ⅲ组）、15例慢性宫颈炎（对照组）的宫颈组织标本中，中期因子的表达与定位。双盲法对免疫组化结果进行评价。结果①宫颈癌组、CINⅠ组、CINⅡ～Ⅲ组及对照组的宫颈组织中，中期因子阳性表达率分别为65．6％，13．3％，40．0％。6．67％，组间比较，差异有显著意义（P〈0．05），中期因子表达随宫颈病变加重而升高。②在宫颈癌组织中，中期因子表达随临床分期的增高而增加．并在宫颈局部癌灶直径≥4cm的癌组中，表达明显增高（P〈0．05）。而各组间病理学类型、组织学分级、宫颈间质浸润深度、有无淋巴结转移之间表达比较，差异无显著意义（P〉0．05）。结论中期因子表达与宫颈病变程度有关，随着宫颈病变的加重，中期因子表达呈逐渐增高趋势。这提示，中期因子与宫颈癌发病，可能有一定关系。

Study on the Correlation Between Midkine Expression and Cervical Cancer

Objective To investigate the expression of midkine （MK） in cervical cancer tissue and its relationship with clinicopathologic feature of cervical cancer. Methods From January 2004 to March 2007, 141 samples were selected from department of Pathology, West China Second University Hospital, Sichuan University, including 96 cases of cervical cancer（the cervical cancer group）, 15 cases of cervical intraepithelial neoplasia grade Ⅰ （the CIN Ⅰ group）, 15 cases of cervical intraepithelial neoplasia grade Ⅱ-Ⅲ （the CIN Ⅱ -Ⅲ group）, 15 eases of chronic cervicitis （the control group）. The expression and localization of midkine were determined by immunohistochemistry. The results for midkine immunostaining were subjected to double blind method scoring, which is analyzed by Chi square test （two tailed, P〈0.05）. Results （①The positive expression rates of midkine in the group of chronic cervicitis, CIN Ⅰ , CIN Ⅱ-Ⅲ and cervical cancer were 6.67%,13.3%,40.0% and 65. 6%, respectively. Midkine expressed higher with the deterioration of cervical lesion （P〈0.05）.② In the group of cervical cancer, the expression of midkine became higher with the process of clinical stage. And its expression was higher in tumors with big size （≥4 cm） （P〈0.05）. Conclusion Expression level of midkine was related to pathological status of cervix. With the process of cervical cancer, midkine expression became stronger, which suggested midkine may participate in the development of cervical cancer.